Homologs of mammalian PTH1 and PTH2 receptors, and a novel PTH3 receptor have been identified in zebrafish (zPTH1, zPTH2, and zPTH3). zPTH1 receptor ligand specificity is similar to that of mammalian PTH1 receptors. The zPTH2 receptor is selective for PTH over PTH-related protein (PTHrP); however, PTH produces only modest cAMP accumulation. A PTH2 receptor-selective peptide, tuberoinfundibular peptide of 39 residues (TIP39), has recently been purified from bovine hypothalamus. The effect of TIP39 has not previously been examined on zebrafish receptors. The zPTH3 receptor was initially described as PTHrP selective based on comparison with the effects of human PTH. We have now examined the ligand specificity of the zebrafish PTH-recognizing receptors expressed in COS-7 cells using a wide range of ligands. TIP39 is a potent agonist for stimulation of cAMP accumulation at two putative splice variants of the zPTH2 receptor (EC 50 , 2.6 and 5.2 nM); in comparison, PTH is a partial agonist [maximal effect (E max ) of PTH peptides ranges from 28 -49% of the TIP39 E max ]. As TIP39 is much more efficacious than any known PTH-like peptide, a homolog of TIP39 may be the zPTH2 receptor's endogenous ligand. At the zPTH3 receptor, rat PTH-(1-34) and rat PTH-(1-84) (EC 50 , 0.22 and 0.45 nM) are more potent than PTHrP (EC 50 , 1.5 nM), and rPTH-(1-34) binds with high affinity (3.2 nM). PTH has not been isolated from fish. PTHrP-like peptides, which have been identified in fish, may be the natural ligands for zPTH1 and zPTH3 receptors. (Endocrinology 141: 3080 -3086, 2000) T HREE RECEPTORS have been identified that are activated by PTH and by related peptide ligands (1-5). The PTH-1 receptor [also known as the PTH/PTH-related protein (PTHrP) receptor] is involved in the principal known physiological action of PTH, control of mineral ion homeostasis (6). This receptor is also activated by PTH-related peptide (PTHrP), a distinct gene product that has 8 of its first 13 N-terminal amino acid residues in common with PTH (7). PTHrP has been proposed to act as an autocrine factor in many tissues (7, 8) and is involved in the development of mammary glands and the formation of endochondral bone (8 -11).
T HREE RECEPTORS have been identified that are activated by PTH and by related peptide ligands (1) (2) (3) (4) (5) . The PTH-1 receptor [also known as the PTH/PTH-related protein (PTHrP) receptor] is involved in the principal known physiological action of PTH, control of mineral ion homeostasis (6) . This receptor is also activated by PTH-related peptide (PTHrP), a distinct gene product that has 8 of its first 13 N-terminal amino acid residues in common with PTH (7) . PTHrP has been proposed to act as an autocrine factor in many tissues (7, 8) and is involved in the development of mammary glands and the formation of endochondral bone (8 -11) .
Rat and human PTH2 receptors are potently activated by a recently identified peptide, tuberoinfundibular peptide of 39 residues (TIP39) (12) . TIP39 has some homology to PTH and PTHrP. Seven of the C-terminal 19 amino acid residues of bovine TIP39 are identical to corresponding residues in bovine PTH, and a number of N-terminal residues are similar (12) . PTH is a weak partial agonist at the rat PTH2 receptor, suggesting that it has little role at this receptor (13) , but PTH is equipotent with TIP39 at the human PTH2 receptor (12, 13) . A PTH2 receptor complementary DNA (cDNA) has recently been isolated from zebrafish (5) . Like human and rat PTH2 receptors it is activated by PTH and not by PTHrP. The presence of a PTH2 receptor in zebrafish was initially interpreted as evidence for the existence of a PTH-like molecule before evolution of the parathyroid gland (5) . However, cAMP accumulation in response to PTH at the zPTH2 receptor was small compared with the response at zPTH1 and zPTH3 receptors and the human (h) PTH2 receptor (4, 5) , and the effect of TIP39 has not been examined. Thus, one aim of this study was to compare the effect of TIP39 on the zPTH2 receptor with those of various PTH peptides.
A third PTH-recognizing receptor (PTH3 receptor) has recently been identified in zebrafish (4) . This receptor was initially described as PTHrP selective, based upon the pharmacological profile of amino-terminal fragments of human PTH and mammalian and fugufish PTHrP. The zebrafish PTH3 receptor is of particular interest because of potential physiological functions of a receptor selective for PTHrP. Recent data suggest the presence of a PTHrP-selective receptor in the rat supraoptic nucleus (SON) that stimulates vasopressin release (14, 15) . The zPTH3 receptor will obviously be of great utility in identifying this mammalian receptor if it represents a close homolog. The selectivity of the zPTH3 receptor for PTHrP was defined with mammalian (the rat and human sequences are the same) and fugufish PTHrP-(1-36) and hPTH-(1-34) (4). The PTHrP-selective effect in the rat SON was defined using mainly rat PTH-(1-34). Thus, the second aim of this study was to characterize further the ligand selectivity of the zPTH3 receptor and in particular to test the effects of rat PTH peptides on its activation. These data could reflect on the likelihood that a PTH3-like receptor is responsible for the PTHrP-selective effects in the SON.
To address the ligand specificity of the zebrafish PTH receptors we evaluated the effects of the three known types of PTH receptor ligands (PTH, PTHrP, and TIP39) in assays of cAMP accumulation, using COS-7 cells transiently expressing the three receptors. At the zPTH2 receptor, as at the rPTH2 receptor, TIP39 displays high potency and efficacy, whereas the PTH peptides are all partial agonists. These data support the hypothesis that TIP39 is an endogenous ligand for the PTH2 receptor and suggest that there may be a TIP39-like molecule in teleosts. At the zPTH3 receptor, rat PTH-(1-34) is more potent than PTHrP-(1-36) and binds to the receptor with high affinity. With the exception of hPTH, the pharmacological profile of the zPTH3 receptor is thus similar to that of the zPTH1 and mammalian PTH1 receptors.
Materials and Methods

Reagents and peptides
All peptides were purchased from Bachem (Torrance, CA), Peninsula Laboratories, Inc. (Belmont, CA), or AnaSpec, Inc. (San Jose, CA). Peptides were dissolved in 10 mm acetic acid at a concentration of 1 or 0.1 mm, the concentration was calculated using the peptide content and weight provided by the supplier. Aliquots of 3 l were stored at Ϫ80 C and used once. The peptides used in this study were hPTH-(1-34), hPTH-(1-84), rat (r) PTH-(1-34), rPTH-(1-84), [Nle 8, 21 ]rPTH-(1-34) amide was prepared using chloramine-T as catalyst, followed by HPLC purification, as previously described (16) . The diiodinated form of the radioligand (4000 Ci/mmol) was used in binding experiments.
Cell culture and transient expression in COS-7 cells
COS-7 cells were grown as previously described (16) . For cAMP accumulation assays, COS-7 cells were transfected as previously described (16) , except for use of 10-cm tissue culture dishes and 10 g plasmid DNA. The next day the cells were transferred after trypsinization to 96-well plates at a density of 50,000 cells/well. For radioligand binding assays, COS-7 cells were plated in 24-well plates at a density of 250,000 cells/well and transfected with 0.5 g/well plasmid DNA. The plasmids used in this study were zPTH1R(FL)/pcDNAI/Amp (encoding the zPTH1 receptor) (4), zPTH2R/pcDNAI/Amp (encoding the zPTH2 receptor) (5), zPTH2R(43)/pcDNAI/Amp (encoding a putative splice variant of the zPTH2 receptor) (5), zeb3-pcDNAI/Amp (encoding the zPTH3 receptor) (4), and pcDNAHAP rP (encoding the human PTH1 receptor incorporating a C-terminal hemagglutinin tag) (16) .
Measurement of cellular levels of cAMP
After removal of medium, transfected COS-7 cells were treated for 40 min at 37 C with 50 l/well cAMP assay buffer [DMEM containing 25 mm HEPES supplemented with 0.1% BSA, 30 m Ro 20 -1724 (Research Biochemicals International, Natick, MA), 100 m [4-(2-aminoethyl)]-benzenesulfonylflouride, and 1 g/ml bacitracin]. This buffer was removed and replaced with 40 l fresh buffer. Test agents were added in a volume of 10 l, and the cells were incubated for an additional 40 min at 37 C. The assay was then terminated by the addition of 50 l 0.1 n HCl and 0.1 mm CaCl 2 . cAMP was quantified by RIA, as previously described (16) . were used 3 days after transfection. Cells were washed once with binding buffer (50 mm Tris, 100 mm NaCl, 5 mm KCl, and 2 mm CaCl 2 , pH 7.5, with HCl, supplemented with 5% heat-inactivated horse serum, 0.5% FBS, 1 g/ml bacitracin, and 100 m [4-(2-aminoethyl)]-benzenesulfonylflouride). To each well was added sequentially 150 l binding buffer, 50 l unlabeled ligand diluted in binding buffer, and 50 l radioligand diluted in binding buffer (ϳ50,000 -100,000 cpm/well). Total binding was defined in the absence of unlabeled ligand, and nonspecific binding was measured in the presence of 3.2 m rPTH-(1-34). Cells were incubated at 15 C for 3 h. The assay plates were then placed on ice for 10 min and washed twice with 0.5ml/well binding buffer. Cell-associated radioactivity was extracted with 0.5 ml 1.0 n NaOH. Samples were transferred to tubes, and radioactivity was measured in a Wallac, Inc. 1470 Wizard ␥-counter. Nonspecific binding was 3-5% of the total counts added for all receptors tested. Total binding was 28 -47% of the added radioactivity for the zPTH1 receptor, 17-23% for the zPTH3 receptor, and 12-33% for the hPTH1 receptor. 
Whole cell radioligand binding assays
Data analysis
, where X is the logarithm of the ligand concentration, and n is Hill slope. For cAMP accumulation data, y is the amount of cAMP accumulated at a given peptide concentration, min is the cAMP level in the absence of ligand, max is the maximum level produced, and LogK is the logEC 50 . For inhibition of radioligand binding, y is the counts per min bound at a given unlabeled ligand concentration, min is nonspecific binding [measured in the presence of 3.2 m rPTH-(1-34)], max is total binding (measured in the absence of unlabeled ligand), and LogK is the logIC 50 . Statistical comparison of multiple means was performed initially by single-factor ANOVA followed by post-hoc analysis with the Newman-Keuls test. Statistical comparison of two means was performed using two-tailed Student's t test, with statistical significance specified by P Ͻ 0.05.
Results
Comparison of PTH and TIP39 activation of the zPTH2 receptor
The zPTH2 receptor has previously been shown to respond to hPTH-(1-34), but not to mammalian or teleost PTHrP (5) . As the rat PTH2 receptor responds better to TIP39 than to a variety of PTH peptides, we compared the effects of TIP39 at the zPTH2 receptor with those of rat and human PTH-(1-34) and fulllength rat and human PTH [PTH-(1-84)]. Previous characterization of the zPTH2 receptor was performed using a splice variant of the zPTH2 receptor, zPTH2(43), that lacks 17 amino acids in the amino-terminal extracellular domain. In this study we extended this characterization to compare the full-length zPTH2 receptor and the zPTH2(43) isoform.
The activity of each of the three known types of PTH receptor ligand was evaluated by measuring cAMP accumulation in COS-7 cells transiently expressing the different receptors. At both isoforms of the zPTH2 receptor, TIP39 produced a 2-to 3.5-fold greater maximal stimulation of adenylyl cyclase than the PTH peptides tested ( Fig. 1 and Table 1 ), an effect that was statistically significant (P Ͻ 0.001, assessed by pairwise comparison of maximal effect (E max ) values with the Newman-Keuls test). The rank order of E max (intrinsic activity) was similar at both isoforms of the receptor
]PTHrP-(1-36) for zPTH2(43); Table 1 ]. The in-trinsic activity values of the peptides were also similar at both receptor isoforms and similar to those for the rat PTH2 receptor ( Table 1 ). The maximal amount of cAMP produced by TIP39 stimulation at the zPTH2 isoform was significantly lower than that produced at the zPTH2(43) isoform (1.3 Ϯ 0.2 vs. 3.0 Ϯ 0.6 pmol/well, respectively). The maximal TIP39 effect at the zPTH(43) receptor was not significantly different from that produced at the rat PTH2 receptor expressed in COS-7 cells (4.3 Ϯ 0.5 pmol/well). In addition to having the greatest maximal effect, TIP39 displayed a potency (EC 50 ) greater than or equivalent to the potency of the PTH peptides examined ( Table 1 ). The EC 50 value for TIP39 was 5.2 nm at the zPTH2 receptor and 2.6 nm at the zPTH2(43) isoform (compared with 0.66 nm at the rat ]PTHrP-(1-36) (OE). The data were fitted to a four-parameter logistic equation using nonlinear regression to obtain estimates of EC 50 and E max ( Table 1) . The data are presented as cAMP produced as a percentage of the maximal response to TIP39, which was assayed in parallel in every experiment. Data represent the mean Ϯ range of duplicate measurements. Data are from representative experiments. The ligands were tested three or four times with similar results. The potency (-logEC 50 ) and maximal effect (E max ) of ligands was measured for stimulation of cAMP accumulation in COS-7 cells transiently expressing the full-length zPTH2 receptor, the putative splice variant zPTH2(43), and the rat PTH2 receptor. The E max was defined as the maximal stimulation by a ligand divided by the maximal response to TIP39, which was assayed in parallel for all ligands. Data represent the mean Ϯ SEM (n ϭ 3 or 4).
ND, Not determined. a Graphical data for the rat PTH2 receptor has been published previously (12) . PTH2 receptor). The potencies of the different PTH peptides varied from 2.6 -150 nm at the zPTH2 receptor and from 6.9 -40 nm at the zPTH2(43) isoform. The EC 50 values for the PTH peptides were not well defined in some cases (Table 1) because the signal to noise ratio in the cAMP RIA was low for these partial agonists (as little as 1.5-fold in some assays). As a result the rank order of EC 50 for the ligands was poorly defined by ANOVA and pairwise comparisons of mean EC 50 values.
Comparison of PTH and PTHrP activation at zPTH1 and zPTH3 receptors
The zPTH3 receptor is a novel PTH receptor with appreciable homology to the zPTH1 receptor (61% amino acid sequence identity) (4). The zPTH3 receptor has previously been shown to be activated with higher potency by [Tyr 36 ]PTHrP-(1-36) than by [Tyr 34 ]hPTH-(1-34). In this study we extended the investigation of ligand activation by including full-length hPTH [hPTH-(1-84)], rPTH-(1-34), rPTH-(1-84), and TIP39. We also tested the effect of these ligands on the zPTH1 receptor to obtain a detailed comparison of zPTH1 and zPTH3 receptor activation.
At the zPTH3 receptor, hPTH-(1-34) displayed lower potency than [Tyr 36 ]PTHrP-(1-36), as reported previously ( Fig.  2 and Table 2 ). However, rPTH-(1-34) was 7-fold more potent than [Tyr 36 ]PTHrP-(1-36) ( Fig. 2 and Table 2 ). These differences were significant (P Ͻ 0.05) as assessed by pairwise comparison of the mean EC 50 values. Using this analysis, the rank order of potency at the zPTH3 receptor was rPTH-(1-34) ϭ rPTH-(1-84) Ͼ [Tyr 36 ]PTHrP-(1-36) Ͼ hPTH-(1-34) Ͼ hPTH-(1-84). The general activation profile of the zPTH3 receptor was similar to that of the zPTH1 receptor ( Fig. 2 and Table 2 ): 1) All of the PTH peptides and the PTHrP analog were full agonists for stimulation of adenylyl cyclase at both receptors. 2) TIP39 produced little or no stimulation at either receptor.
3) The N-terminal fragments rPTH-(1-34) and hPTH-(1-34) were equivalently potent or more potent than full-length PTH of the corresponding species, indicating that the N-terminal fragment of PTH is sufficient for full and potent activation of adenylyl cyclase at these receptors. 4) The difference between mean ligand potency at the zPTH1 and zPTH3 receptors was less than 10-fold, with the exception of hPTH-(1-34), which was 18-fold more potent at the zPTH1 receptor ( Table 2 ). The maximal hPTH-(1-34)-stimulated cAMP level at zPTH1 and zPTH3 receptors was not significantly different (2.5 Ϯ 0.5 and 3.3 Ϯ 0.6 pmol/well, respectively). Neither of these values was significantly different from the hPTH-(1-34) E max at the human PTH1 receptor expressed in COS-7 cells (3.8 Ϯ 0.4 pmol/well) (12). ]PTHrP-(1-36) (OE). The data were fitted to a four-parameter logistic equation using nonlinear regression to obtain estimates of EC 50 and E max ( Table 2 ). The data are presented as cAMP produced as a percentage of the maximal response to hPTH-(1-34), which was assayed in parallel in every experiment. Data represent the mean Ϯ range of duplicate measurements. Data are from representative experiments. The ligands were tested three or four times with similar results.
Measurement of TIP39 and rPTH-(1-34) binding affinities at zPTH1 and zPTH3 receptors
Although TIP39 produced little or no activation of zPTH1 and zPTH3 receptors, this finding does not address whether the ligand can bind to these receptors. Binding of TIP39 was measured in competition assays using [ (Fig. 3) . The IC 50 for TIP39 at the zPTH3 receptor (350 nm) was 8-fold lower than that at the zPTH1 receptor and approximately equal to that at the human PTH1 receptor (Table 3) . rPTH-(1-34) bound with high affinity (3-14 nm) to all three of these receptors ( Fig. 3 and Table 3 ). The IC 50 for rPTH-(1-34) at the human PTH1 receptor (14 nm) was comparable with that determined previously (16) . The affinity of TIP39 for the human PTH1 receptor in whole COS-7 cells (350 nm) was similar to that measured for the receptor in isolated membranes prepared from these cells (160 nm; graphical data not shown).
Discussion
In this study we compared the ligand specificity for activation of zebrafish PTH1, PTH2, and PTH3 receptors. The ]rPTH-(1-34) amide binding by unlabeled TIP39 (F) and unlabeled rPTH-(1-34) (E) was measured as described in Materials and Methods. Data points represent the mean Ϯ SEM of triplicate measurements. Data were fitted to a four-parameter logistic equation to provide estimates of the inhibitory potency (IC 50 ) and the slope of the curve (Hill slope; Table 3 ). The data are from representative experiments. Three experiments were performed for the zPTH1 and zPTH3 receptors, and two for the hPTH1 receptor. 
ND
The potency (-logEC 50 ) and maximal effect (E max ) of ligands were measured for stimulation of cAMP accumulation in COS-7 cells transiently expressing zPTH1 and zPTH3 receptors. The E max was defined as the maximal stimulation by a ligand divided by the maximal response to hPTH-(1-34), which was assayed in parallel for all ligands. The ligand selectivity for the two receptors was calculated by dividing the EC 50 for activation of the zPTH3 receptor by that for the zPTH1 receptor. ND, Not determined.
Data represent the mean Ϯ SEM (n ϭ 3 or 4). a Response to 320 nM TIP39.
major findings were 1) TIP39 is 2-to 3-fold more efficacious than PTH peptides at the zPTH2 receptor; 2) the zPTH3 receptor is not PTHrP-selective when the activity of [Tyr 36 ]PTHrP-(1-36) is compared with activation by rPTH- (1-34) ; and 3) the pharmacological profile of the zPTH3 receptor closely resembles that of the zebrafish, frog (17) and mammalian PTH1 receptor [with the exception of the activity of hPTH-(1-34)]. The activity of the ligands was measured in cAMP accumulation assays using COS-7 cells transiently expressing the receptor. Despite the heterologous nature of the expression system, the maximal ligand-stimulated cAMP level was equivalent to that of corresponding mammalian receptors for the zPTH1 and zPTH3 receptors and for a putative splice variant of the zPTH2 receptor [zPTH2(43), which lacks 17 amino acids in the extracellular N-terminal domain]. This finding suggests that these receptors are efficiently coupled to cAMP production in COS-7 cells. In addition, the maximal responses were similar for the three zebrafish PTH receptors. These considerations suggest that it is reasonable to compare the pharmacological profiles of the zebrafish receptors with each other and with the profile of their mammalian homologs.
At both isoforms of the zPTH2 receptor, bTIP39 displays high efficacy and potency despite the considerable evolutionary distance between the cow and the zebrafish. This observation strongly suggests that TIP39 is an endogenous ligand for the PTH2 receptor. The existence of the zebrafish PTH2 receptor led initially to the suggestion that PTH is present in bony fish, as this receptor is activated by PTH, but not by PTHrP (5). However, as TIP39 is a better agonist at the receptor, the existence of the zPTH2 receptor can be interpreted to suggest the presence of a TIP39-like molecule in this species rather than lending support to the presence of PTH. The possibility that a teleost homolog of PTH might display a much higher efficacy than mammalian PTH cannot be ruled out. However, mammalian PTH strongly activates zPTH1 and zPTH3 receptors, suggesting that a species difference minimally affects the efficacy of PTH at these receptors. Overall, the profile of ligand activation of the zPTH2 receptor isoforms closely resembles that of the rPTH2 receptor, for which PTH peptides are also partial agonists (13) . This similarity suggests that the PTH2 receptor has been functionally well conserved through evolution. However, PTH is a full agonist at the hPTH2 receptor (12, 13) . One possible view is that the PTH2 receptor has mediated the effects of TIP39 through evolution and that in humans the PTH2 receptor has gained full responsiveness to PTH.
The zebrafish PTH3 receptor has previously been demonstrated to be selective for mammalian and teleost PTHrP (14) . Finally, centrally administered PTHrP-(1-34) stimulates vasopressin release in vivo (15) . In all of these experiments, PTHrP selectivity was demonstrated by comparison with rPTH-(1-34), which had little or no effect. We therefore examined the effect of rPTH-(1-34) at the zPTH3 receptor. In cAMP accumulation assays, rPTH-(1-34) was significantly more potent than [Tyr 36 ]PTHrP-(1-36) at the zPTH3 receptor. In addition, rPTH-(1-34) displayed high affinity for this receptor in radioligand binding assays (IC 50 ϭ 3.2 nm). These data indicate that unless the PTH3 receptor is much less functionally conserved than the PTH1 and PTH2 receptors, this receptor is unlikely to mediate the PTHrP-selective effect observed in the rat SON. We found that the [Tyr 36 ]PTHrP selectivity over hPTH-(1-34) at the zPTH3 receptor was only 3-fold, which is less than that previously reported (21-fold) (4). This difference may have resulted from the use of a slightly different ligands; hPTH-(1-34) and [Tyr 36 ]PTHrP-(1-36) were used in this study, whereas [Tyr 34 ]hPTH-(1-34) amide and [Tyr 36 ]PTHrP-(1-36) amide were used previously. In addition, the previous study employed different cell culture conditions after transfection (to maximize receptor number), which could have contributed to the higher potency observed for [Tyr 36 ]PTHrP-(1-36). Overall, the profile of the zPTH3 receptor for stimulation of adenylyl cyclase resembles those of zebrafish, frog, and mammalian PTH1 receptors (1, 2, 4, 17) . However, these receptors may differ significantly in coupling to production of inositol phospholipids; ligand activation of the zPTH1 receptor stimulates inositol phospholipid accumulation in COS-7 cells, whereas the zPTH3 receptor is not detectably coupled to this second messenger pathway.
A teleost PTHrP molecule is a candidate for an endogenous ligand of the zPTH1 and zPTH3 receptors (4). PTHrPlike immunoreactivity and messenger RNA have been detected in several fish species (18 -21) , and a PTHrP-like sequence has been identified in the pufferfish genome (FUGU Landmark Mapping Project Database clones 115E01AC6 and 155E01eB5). The presence of PTH in teleosts remains to be conclusively demonstrated. A short PTH-like DNA sequence encoding 10 amino acids has been amplified from rainbow trout genomic DNA (22) , and PTH-like immunoreactivity has been described in teleosts (18, 19) . Although the pharmacological profiles of the zebrafish receptors do not exclude the existence of teleost PTH, the presence of these receptors does not provide a strong argument for the presence of this peptide, as all three receptors respond equally well or better to other ligands.
The family of PTH receptors and the family of PTH-like peptides has expanded dramatically in the last several years with the discovery of PTH2 and PTH3 receptors and TIP39. The isolation of all three receptors from zebrafish provides the means to study the evolution and biological roles of these receptors. The receptors should also prove useful for studying the structural basis of ligand selectivity. The comprehensive pharmacological evaluation of the receptors in this study provides a sound basis for the further investigation of this diverse, physiologically important receptor and ligand family.
